These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38270277)

  • 1. Soluble B-cell maturation antigen in multiple myeloma.
    Costa BA; Ortiz RJ; Lesokhin AM; Richter J
    Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
    Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
    Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

  • 7. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
    Martino M; Paviglianiti A
    Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
    Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
    Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
    Chen H; Yu T; Lin L; Xing L; Cho SF; Wen K; Aardalen K; Oka A; Lam J; Daley M; Lu H; Munshi N; Anderson KC; Tai YT
    Blood Cancer J; 2022 Aug; 12(8):118. PubMed ID: 35973981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
    Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
    Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCMA-targeted immunotherapy for multiple myeloma.
    Yu B; Jiang T; Liu D
    J Hematol Oncol; 2020 Sep; 13(1):125. PubMed ID: 32943087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rethinking mechanisms of neurotoxicity with BCMA directed therapy.
    Mohyuddin GR; Banerjee R; Alam Z; Berger KE; Chakraborty R
    Crit Rev Oncol Hematol; 2021 Oct; 166():103453. PubMed ID: 34461271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
    Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
    Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS.
    Shen X; Dong X; Shi J; Chen H; Lan Y; Lim AC; Xie F; Ang A; Kratzer A; Rock DA; Rock BM
    Clin Chem; 2024 Jan; 70(1):339-349. PubMed ID: 38175591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.